Setup

Abaxx Technologies (ABXXF) is a Singapore-regulated commodity exchange and clearinghouse building physically-deliverable futures benchmarks in LNG, gold, silver, carbon, and weather derivatives, alongside a technology suite (MarketOS, ID++) targeting T+0 collateral mobilization in regulated markets. We're looking at it now because Q1 2026 earnings revealed April ADV of 12,174 contracts/day — up 8x from Q4 2025's 1,500/day — while the CEO disclosed on the call that sell-side still prices exchange success at 20-25% probability and no analyst has published a price target.

What the Filing Says

Volume inflection: Q4 2025 ADV 1,500/day → Q1 2026 3,800/day (+157% QoQ) → April 2026 12,174/day (+220% vs Q1). April volume exceeded all of 2025 combined. Single-day record May 14: 50,277 contracts. NPA Asia LNG contract at >40% of JKM (Platts benchmark) volume per management.

Institutional flywheel: Joe Raia (Q&A): "Within a week of Trayport going live, three large banks that were looking at us but hadn't committed came in requesting access" — forcing FCM onboarding for all FCM clients. 9,800+ Trayport participants now see Abaxx markets. EU ACER registration independently verified as Organised Market Place.

Management's own probability framing: CEO Josh Crumb: "the sell-side is effectively pricing the possibility of our exchange succeeding at somewhere between 20 and 25 percent... and assigning zero value to the technology suite."

Technology: Alta partnership for T+0 collateral is the first commercial MarketOS step. Regulatory approval still required. No pricing disclosed. Full commercialization discussion explicitly deferred to August 2026 call.

Cash: CAD $85M liquid, ~CAD $30M/year burn. "Three to six quarters" capital sufficiency from Q1.

What the Market Thinks

$43 USD, $1.6B USD market cap. Four analysts covering, all Buy/Strong Buy — zero price targets published. Consensus success probability: 20-25% per CEO's direct characterization.

Back-solving from the 22% consensus probability: the market implies an "inflects" state value of CAD ≈$4.4B — a +100% from current. If success probability is actually 35% (our view, derived from evidence below), expected return is +19% over 12 months vs market's +4%. Over 5 years in the inflects state: +655% (exchange at 100k+ ADV + tech revenue). Alpha Sharpe at 12 months: 0.22 — below investable threshold at full size, argues for staged entry.

Why the Gap Exists

Three specific disconnects:

1. Volume data is in no model. Without disclosed RPC, no analyst can convert ADV to revenue — hence zero price targets despite 100% buy ratings. At our estimated CAD $5/contract RPC (back-solved from management's stated revenue trajectory), April's 12,174 ADV implies ~CAD $15M annualized run rate. When RPC is disclosed on the August call, first targets follow within 30-60 days and create a new institutional anchor above current prices.

2. Insider buying not synthesized. Three directors bought open-market in the same 6-week window: Nancy Seah CAD $1.37M (May 12), Jeffrey Currie CAD $153k (April 2-7), Catherine Flax CAD $151k (April 2-8). Currie is former Goldman Sachs Global Head of Commodities Research, 30 years. He has been a director since 2023 — not a celebrity hire, a practitioner who has watched the order book for three years and chose to buy at current prices. Net insider: +CAD $1.57M. Contra: Steve Fray (Senior Officer) sold 2,500 shares ($104k) in the same window — small, likely personal liquidity, but noted.

3. China silver angle not processed. Management's thesis for the silver contract (launched May 22) centered on solar/electronics demand — declining. PV silver demand fell 6% in 2025, forecast -19% in 2026 due to manufacturing thrifting. The stronger structural case is China's silver export controls (effective January 1, 2026), which disrupted 60-70% of global refining capacity. Shanghai physical silver hit +12% premium vs London. Asian buyers needing non-China 4-nine silver delivery now have a structural incentive to use the Singapore-vaulted contract. Management underemphasized it; the market hasn't synthesized it.

Risks

1. Gold price dependency. Gold drives ≈90% of current volume and ≈18% of total return variance. We have no edge on gold's direction. Institutional GLD positioning is bearish (P/C 1.66, 32 puts vs 4 calls unusual activity as of 2026-05-25). A sustained gold bear reduces Abaxx volumes before the exchange diversifies. This is the largest unmodeled risk — not in any bear case currently published.

2. Market maker concentration. Abaxx cannot disclose participants by regulation. If 2-3 prop firms drive the majority of current volume, one exit causes a step-function ADV decline. April's 12k/day could become 3k/day.

3. Cash runway. CAD $85M at CAD $30M/year burn = ≈2.8 years. Dilutive capital raise before end-2026 is 40% probable if exchange revenue and tech don't accelerate together.

4. Episodic volume pattern. Management's own characterization: "highly nonlinear with fits and starts." May 14 record (50k) vs April average (12k) shows lumpiness — the average, not the record, is signal.

Catalysts

August 2026 call (primary gate, dates TBD): Technology pricing disclosure (55%) + Q2/Q3 ADV report (50%). If RPC is disclosed, first analyst targets follow within 30-60 days (70% by October 31).

Silver 90-day volume (by August 20): First external test of the China supply-chain bifurcation thesis (30% for 500+ ADV).

U.S./China institutional desk (by November 30): Management's explicit "next flywheel" trigger — flagged as not yet onboarded (35%). Any 8-K confirming a named desk is the next Trayport moment.

What Would Change Our Mind

• Q2 or Q3 ADV below 5,000/day for two consecutive months — volume inflection was transient
• Gold corrects >20% and Abaxx ADV falls proportionally — exchange is levered gold volatility, not a durable mechanism
• Technology commercialization explicitly deferred past H1 2027 on August call — tech optionality confirmed at zero
• Capital raise below CAD $25/share — dilutive signal, thesis in distress
• Single market maker identified as >60% of volume who then reduces exposure

Evidence